{"id":4430,"date":"2026-11-19T09:00:00","date_gmt":"2026-11-19T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4430"},"modified":"2026-11-19T20:46:05","modified_gmt":"2026-11-20T00:46:05","slug":"second-evotec-bms-molecular-glue-candidate-reaches-ind","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4430","title":{"rendered":"Second Evotec BMS Molecular Glue Candidate Reaches IND"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Evotec_BMS_Technology_and_Modalities-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4443\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Evotec_BMS_Technology_and_Modalities-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Evotec_BMS_Technology_and_Modalities-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Evotec_BMS_Technology_and_Modalities-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Evotec_BMS_Technology_and_Modalities-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Evotec_BMS_Technology_and_Modalities.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Evotec; Bristol Myers Squibb<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>FDA IND acceptance<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Cereblon E3 ligase modulator (molecular glue)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Second partnered candidate (undisclosed)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Undisclosed<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Undisclosed<\/p>\n<h4>Summary<\/h4>\n<p>Evotec reported November 19 that the FDA accepted an IND for a second candidate from its Bristol Myers Squibb molecular-glue collaboration. It is a development-enabling regulatory step, not clinical data or approval.<\/p>\n<p>The new cereblon E3 ligase modulator is expected to enter Phase 1 in 2027. A first partnered candidate entered a Phase 1 renal-cell carcinoma trial in March 2026. Evotec did not disclose the second candidate\u2019s target, indication, potency, pharmacology or payment amount.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> a second IND suggests the partnership can repeatedly generate development candidates.<\/p>\n<p><strong>Interpretation B:<\/strong> IND clearance reflects permission to begin human testing, not target validation or scalable platform economics. CRBN recruitment, substrate selectivity, tissue exposure, degradation kinetics, resistance and off-target neosubstrates remain unresolved. The timing of first dosing and clinical response will determine whether this becomes a meaningful competitive threat.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Molecular glues induce proximity between an E3 ubiquitin ligase such as cereblon and a target protein, triggering ubiquitination and degradation. The second asset\u2019s target disease is undisclosed.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Primary Evotec release verifies the milestone; FDA dossier is not public.<\/li>\n<li>Missing: asset identity, trial record, toxicology, IP details and economics.<\/li>\n<li>Upgrade: registered trial with human PD and tolerability.<\/li>\n<li>Downgrade: prolonged delay or safety halt.<\/li>\n<li>Falsifier: inability to dose at degradation-relevant exposure.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The event modestly validates discovery throughput while leaving therapeutic value undetermined.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 3 of 5. Signal Direction: neutral. Confidence in Facts: High. Confidence in Interpretation: Low to Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Evotec reported November 19 that the FDA accepted an IND for a second candidate from its Bristol Myers Squibb molecular-glue collaboration. It is a development-enabling regulatory step, not clinical data or approval.<\/p>\n","protected":false},"author":1,"featured_media":4443,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[101,1548,380],"class_list":["post-4430","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-bristol-myers-squibb","tag-evotec","tag-molecular-glue"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4430","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4430"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4430\/revisions"}],"predecessor-version":[{"id":4446,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4430\/revisions\/4446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4443"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4430"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4430"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4430"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}